Compare Incyte Corporation (INCY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Materials Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Materials Select Sector SPDR Fund trades at $53.17. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | XLB | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | — |
52-Week High | $129.93 | $53.62 |
52-Week Low | $81.61 | $42.23 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
XLB trades at $52.58, down 1.13% on the day, with a bullish technical signal from moving averages but mixed oscillator readings. The stock recently crossed below its 200-day moving average, signaling potential trend change. A dividend of $0.19 is scheduled for June 2026. Recent news highlights materials sector strength from AI infrastructure demand and geopolitical supply chain shifts.
Outlook remains cautiously optimistic given sector tailwinds from AI and infrastructure spending, though cyclical risks and valuation concerns after recent gains pose headwinds. The technical setup suggests near-term consolidation around $53 support with resistance at $54.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
